Loss of articular cartilage through injury or disease presents major clinical challenges also because cartilage has very poor regenerative capacity, giving rise to the development of biological approaches. As autologous blood product, platelet-rich plasma (PRP) provides a promising alternative to surgery by promoting safe and natural healing. Here we tested the possibility that PRP might be effective as an anti-inflammatory agent, providing an attractive basis for regeneration of articular cartilage, and two principal observations were done. First, activated PRP in chondrocytes reduced the transactivating activity of NF-kB, critical regulator of the inflammatory process, and decreased the expression of COX2 and CXCR4 target genes. By analyzing a panel of cytokines with different biological significance, in activated PRP we observed increases in hepatocyte growth factor (HGF), interleukin-4 and tumor necrosis factor-α (TNF-α). HGF and TNF-α, by disrupting NF-kB-transactivating activity, were important for the anti-inflammatory function of activated PRP. The key molecular mechanisms involved in PRP-inhibitory effects on NF-kB activity were for HGF the enhanced cellular IkBα expression, that contributed to NF-kB-p65 subunit retention in the cytosol and nucleo-cytoplasmic shuttling, and for TNF-α the p50/50 DNA-binding causing inhibition of target-gene expression. Second, activated PRP in U937-monocytic cells reduced chemotaxis by inhibiting chemokine transactivation and CXCR4-receptor expression, thus possibly controlling local inflammation in cartilage. In conclusion, activated PRP is a promising biological therapeutic agent, as a scaffold in micro-invasive articular cartilage regeneration, not only for its content of proliferative/differentiative growth factors, but also for the presence of anti-inflammatory agents including HGF.
ABSTRACTd-a-Tocopherol, but not d-jJ-tocopherol, negatively regulates proliferation of vascular smooth muscle cells at physiological concentrations. d-c-Tocopherol inhibits protein kinase C (PKC) activity, whereas d-13-tocopherol is ineffective. Furthermore d-18-tocopherol prevents the inhibition of cell growth and of PKC activity caused by d-ctocopherol. The negative regulation by d-cv-tocopherol of PKC activity appears to be the cause and not the effect of smooth muscle cell growth inhibition. d-a-Tocopherol does not act by binding to PKC directly but presumably by preventing PKC activation. It is concluded that, in vascular smooth muscle cells, d-c-tocopherol acts specifically through a nonantioxidant mechanism and exerts a negative control on a signal transduction pathway regulating cell proliferation.Vascular smooth muscle cell (vascular SMC) proliferation represents a significant event in a number of diseases such as arteriosclerosis and hypertension (1-4). Smooth muscle proliferation is controlled by growth factors released from blood cells (1, 2, 5), by inhibitors or stimulants produced by the vessel wall cells (6, 7), by tocopherols, and by active oxygen species (8, 9). Evidence indicates that experimental atherosclerosis and foam cell formation can be effectively retarded by antioxidants (10-12). In addition, supplementation of human subjects with antioxidants has been shown to increase the resistance of their low density lipoproteins to oxidation and to protect against arteriosclerosis (13-16). As antioxidants, tocopherols may stimulate in some cases cell proliferation by removing inhibitory lipid peroxides (17-22). However, d-atocopherol has also a direct effect as cell-growth inhibitor, and this effect is not obviously mediated by its reduction-oxidation properties (23)(24)(25).PKC participates in one of the major signal transduction systems triggered by the external stimulation of cells by various ligands including hormones, neurotransmitters, and growth factors (26). Activation of PKC by phorbol esters may be responsible for their growth-promoting activity. d-aTocopherol has been shown to inhibit PKC activity in a number of cell lines and, in particular, in SMC. The mechanism of this inhibition has not yet been clarified (23)(24)(25).In the present study PKC inhibition has been found to be the basis of the inhibition of cell proliferation by d-a-tocopherol.Moreover PKC inhibition has been found to be cell cycle dependent, a result inconsistent with a direct interaction between PKC and d-a-tocopherol. Finally, the inhibitory specificity of d-a-tocopherol versus d-3-tocopherol and their mutual competition suggest a nonantioxidant mechanism to be at the basis of its action. MATERIALS AND METHODSGrowth media and serum were from GIBCO; A7r5 rat aortic SMC were from the American Type Culture Collection; phorbol 12-myristate 13-acetate (PMA) and streptolysin-O (25,000 units) were from Sigma; calphostin C, calyculin A, and okadaic acid were from LC Services (
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.